TS2: Introduction to Small Molecule Drug Discovery and Development
September 27-28, 2017
Day 1 (Wednesday, September 27) 3:30 PM – 6:30 PM
Day 2 (Thursday, September 28) 9:00 AM – 5:00 PM
Instructors:
H. James Harwood Jr., Ph.D., Founder and CEO, Delphi BioMedical Consultants, LLC
Geraldine Harriman, Ph.D., Founder and CSO, HotSpot Therapeutics, Inc.
About this Training Seminar:
This 1.5-day lecture-based interactive seminar focuses on strategies for identifying drug discovery targets, discovering and characterizing small molecule hits, and developing structure-activity relationships to advance hits through lead optimization, preclinical development, and clinical evaluation. Participants will learn the stages and processes required to advance programs from idea to clinic, through examples and case studies. This seminar is intended for scientists in either academia or industry who would like to become more familiar with small molecule drug discovery and development.
Topics to be Covered in the Seminar:
- Stages of drug discovery, development, and clinical evaluation
- Strategies for identifying key drug discovery targets
- Screening strategies for discovering and characterizing small molecule modulators
- Use of structure-based drug design to develop structure-activity relationships
- In vitro, in culture, and in vivo strategies for optimizing drug-like properties, efficacy and pharmacokinetics
- Strategies for selecting developmental candidates
- Requirements for advancing a developmental candidate to clinical trials
- Biomarkers – translation of efficacy in experimental animals to efficacy in humans
- Design of clinical trials – proof-of-concept efficacy studies
- Design of clinical trials – outcome efficacy studies
About the Instructors:
H. James Harwood Jr., Ph.D., Founder and CEO, Delphi BioMedical Consultants, LLC
James Harwood, a biochemist and lipid enzymologist, brings over 40 years of research expertise in studying the physiological and pharmacologic modulation of key enzymes and receptors involved in the regulation of intermediary metabolism and over 30 years of broad based expertise in drug discovery and development in the pharmaceutical industry. Presently, Jim is Founder and CEO of Delphi BioMedical Consultants LLC, a consulting practice servicing the pharmaceutical and biotechnology industries, Adjunct Professor in the Department of Cellular and Molecular Biology at the University of Rhode Island where he teaches Biochemistry and advises pre-health profession students, and Adjunct Professor in the Department of Pathology at the Wake Forest University School of Medicine where he collaborates to study metabolic diseases in non-human primates. Prior to this, Jim was Principal Research Investigator in the Department of Cardiovascular and Metabolic Diseases at Pfizer Global R&D where some of his key projects included discovery and development of cholesterol synthesis inhibitors, cholesterol absorption inhibitors, fatty acid synthesis inhibitors, fat absorption inhibitors, and fat metabolism enhancers. Prior to these activities, he was Assistant Professor in the Departments of Medicine and Pharmacology at the University of Florida where he studied the physiological and pharmacologic regulation of cholesterol metabolism in experimental animals and in humans. Jim earned his Ph.D. in Biochemistry in 1982 from Purdue University and has authored over 80 publications in scientific journals.
Geraldine Harriman, Ph.D., Founder and CSO, HotSpot Therapeutics, Inc.
Gerry Harriman, a medicinal chemist by training, has been in pharmaceutical research for over 20 years. Her broad-based training has allowed her to successfully advance 10 drug candidates into clinical development across several therapeutic areas including inflammation, oncology, CNS and metabolic disease. Presently, Gerry is Founder and Chief Scientific Officer at HotSpot Therapeutics. Prior to this, she held several senior positions in Boston biotech. She was Vice President and Head of the Nimbus Apollo subsidiary at Nimbus Therapeutics, Vice President and Head of Chemistry at Galenea, and Co-Lead of the Inflammation Therapeutic Area at Millennium Pharmaceuticals. She is the author/inventor of over 70 scientific publications and patents.
Each CHI Training Seminar offers 1.5 Days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.
Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed no additional books will be available.
Though CHI encourages track hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and NOT engaging in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.
